Cardiol Therapeutics Inc. (CRDL)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Quarterly Financials (CAD)
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (10.2M) | (8.0M) | (9.7M) | (7.9M) |
| Net Income | (10.0M) | (7.2M) | (10.8M) | (6.1M) |
| Diluted EPS | (CAD 0.12) | (CAD 0.10) | (CAD 0.05) |
Annual Financials (CAD)
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (41.3M) | (29.8M) | (40.3M) | (34.3M) |
| Net Income | (30.9M) | (28.1M) | (36.7M) | (33.8M) |
| Diluted EPS | (CAD 0.49) | (CAD 0.44) | (CAD 0.51) | (CAD 0.39) |